Stroke in T2DM-mice exacerbates NAFLD progression while CD133 + Exo treatment significantly reduces steatosis, fibrosis, NAS, and ALT activity. The gene discussed is PROM1; the disease is metabolic dysfunction-associated steatotic liver disease.